Boan Biotech and CP Qingdao deal re Boyoubei® (biosimilar denosumab)

Jan 10, 2023

Luye Pharma announced that its subsidiary Boan Biotech has signed an agreement with CP Pharmaceutical Qingdao Co., Ltd. (CP Qingdao) to grant CP Qingdao the right to commercialise Boyoubei® (biosimilar denosumab) in mainland China.  Boyoubei was approved by China’s NMPA in November 2022.

Print Page Mail Article